Karyopharm Therapeutics(KPTI) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Targeting Disease at the Nuclear Pore "We have taken a significant step that improves our capital structure, strengthening our opportunity to realize the full value of three potential new indications for selinexor. We are strongly positioned for our next stage of growth, driven by our focused and rapidly advancing late-stage pipeline with expected data readouts from our three ongoing Phase 3 trials next year," said Richard Paulson, President and Chief Executive Officer of Karyopharm. First Quar ...